News
AbbVie, Gilead Sciences and GSK marked World Hepatitis Day on Monday, outlining the need to tackle the stigma and ...
Shares of GSK fell to below $30 around the time of the demerger, but have since recovered to about $36. The 20% gain over 34 ...
The JAK-inhibitor will be available to veterinarians and itchy dog owners in the United Kingdom by the end of Q3 2025.
Britain's GSK and China's Jiangsu Hengrui Pharmaceuticals have agreed on a $500 million deal to develop up to a dozen new ...
The deal, which focuses first on a COPD drug GSK believes holds “best-in-class” potential, could involve a dozen medicines ...
GSK is paying $500M upfront for rights to a series of Hengrui drugs, the latest case of a pharma company looking to a Chinese ...
GSK has moved to shore up its R&D pipeline with a strategic-level deal with China's Jiangsu Hengrui Pharma that spans a dozen drug candidates and could be worth up to $12.5 billion.
The leading Eczema Companies such as Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun ...
London: GSK plc has received approval for Blenrep in the European Union (EU) for the treatment of adults with relapsed or ...
European Union approves GSK’s Blenrep combinations to treat relapsed/refractory multiple myeloma: London, UK Saturday, July 26, 2025, 11:00 Hrs [IST] GSK plc announced the appro ...
The agency weighed safety data and a new dosing regimen to recommend approval of the treatment for early Alzheimer's disease in certain patients.
Lilly’s appeal of an earlier, negative recommendation from a key EMA committee has worked out in its favor, and puts the drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results